Avian adenovirus CELO is a novel adenovirus vector system with the advantages of efficient production, high virion stability, and the absence of crossreactivity with Ad5-neutralizing antibodies. In this study, we evaluated the anticancer efficacy of a CELO vector encoding the herpes simplex virus type 1 thymidine kinase, a prodrug-activating therapeutic gene. Vectors carrying the gene for HSV-tk or EGFP under the control of the HCMV promoter in place of the ''nonessential'' region of the CELO genome were constructed. Anticancer activity of the CELO-TK vector was studied in vitro, in human and murine tumor cells in cell culture, and in vivo, in established subcutaneous murine B16 melanoma tumors in C57BL/6 mice. The CELO-TK vector mediated delivery of functional HSV-tk to tumor cell lines in cell culture. Comparison of the CELO-TK vector to a first-generation human adenovirus type 5 vector Ad5-TK in cultured H1299 cells showed equal levels of functional activity at increasing multiplicities of infection with CELO-based vector. CELO vectors allowed for transduction and expression of EGFP and HSV-tk genes in subcutaneous melanoma tumors in C57BL/6 mice. Intratumoral injections of CELO-TK followed by ganciclovir administration resulted in suppression of tumor growth and significantly increased the median of survival. The results of the study demonstrated the efficacy of CELO vector as a vehicle for the delivery of prodrug-activating genes such as HSV-tk to tumor cells in vitro and in vivo. Cancer Gene Therapy ( 1 This experimental approach to cancer treatment is currently in a transition from promise to reality with recent approval of an adenovirus (Ad) vector expressing p53 for use in clinics and with many more vectors in late stages of clinical trials.
W ith approximately 10 million new cases of cancer diagnosed each year worldwide, novel approaches in antitumor drug development are required to provide effective remedies for the disease. The goal of cancer gene therapy is to develop efficient and specific anticancer agents by identifying therapeutic genes and by designing vector systems for delivery of these genes into tumor cells. 1 This experimental approach to cancer treatment is currently in a transition from promise to reality with recent approval of an adenovirus (Ad) vector expressing p53 for use in clinics and with many more vectors in late stages of clinical trials. 2 At the same time, new generations of cancer gene therapy vectors are being developed that will provide higher levels of efficacy, specificity, and cost-effectiveness.
Whereas human Ad type 5 (Ad5) is a common platform for Ad vectors for the in vitro and in vivo delivery of genes, 3, 4 non-human adenoviruses (Ads), also referred to as ''xenogeneic'' vectors, are currently emerging as alternative or additional gene delivery vehicles. 5, 6 Avian Ad CELO (FAV-1) is a novel non-human Ad vector that has potential advantages for the development of anticancer vectors including: (i) the absence of pre-existing immunity to CELO in the human population, 7 (ii) the absence of immunological crossreactivity between virions of Ad5 and CELO, 8 which allows for in vivo transduction by CELO vectors in the presence of anti-Ad5 neutralizing antibodies, 9 (iii) higher stability of CELO virions as compared to Ad5 virions, 7 (iv) the natural inability of CELO to replicate in non-avian cells, which renders CELO vectors gene delivery vehicles rather than replicative agents in mammalian cells, 7 (v) the ability of CELO vectors to grow in noncomplementing cells resulting in the absence of recombination with the homologous viral DNA sequences in the genome of a complementing cell line, and the absence of contaminating wild-type (wt) virus in vector preparations, 7 and (vi) the availability of a highly efficient large-scale production system, embryonated chicken eggs.
The effectiveness of production is an important factor that determines the availability of a drug to patients. The history of the use of human Ads in clinics is limited to live Ad4/Ad7 vaccine in military recruits in the US. Production of the vaccine was terminated by the sole manufacturer for economic reasons stressing the importance of cost-effective virus production as a consideration in viral vector design. 10 Whereas large-scale preparations of human Ads and the majority of non-human Ads can only be produced in cell culture, CELO virus and nondefective CELO vectors can be produced not only in cell culture but also in embryonated hens' eggs. 7, 8 An average yield of wt CELO in egg culture was demonstrated to reach 1.76 Â 10 12 virus particles per egg (0.42 mg of CELO protein per egg or 0.5 mg of virus per egg). 7, 8 Recombinant CELO with deletion of the ''nonessential'' region produced an average yield of 1.24 Â 10 12 virus particles per egg (0.3 mg of CELO protein per egg). 7 The ability to replicate efficiently in chicken embryos is an important feature of CELO vectors. It allows for costeffective production of high-titer vector preparations by eliminating the expenses associated with culture of mammalian cells such as glass-or plasticware, media, growth factors (sera), and equipment such as CO 2 incubators. Automated machines for egg inoculation and harvesting (Rame´-hart, Mountain Lakes, NJ) that are able to process 30,000 eggs per hour are used commercially to reduce the workload and to increase the cost-effectiveness of production. Chicken embryos are used currently to produce viral vaccines for humans, [11] [12] [13] including yellow fever, live attenuated influenza A and inactivated influenza A vaccines. 11, 12 Egg culture remains the most efficient large-scale production system for influenza A vaccine as compared to various mammalian cell culture systems. 14 The results of recent studies, which show the absence of adverse effects in vaccinees, underscore the safety of this production system. 13 One of major characteristics of an anticancer drug is its efficacy. The efficacy of cancer gene therapy depends largely on the ability of a vector to deliver therapeutic genes to a substantial proportion of cells within a tumor and on the presence of a ''bystander effect'', which amplifies the anticancer effect from initially transduced cells. Thymidine kinase of human herpes simplex virus type 1 (HSV-tk) converts the nontoxic prodrug ganciclovir (GCV) into GCV-monophosphate (GCV-MP), which after subsequent phosphorylation to GCV-triphosphate by cellular kinases, becomes incorporated into nascent DNA chains of dividing (e.g. tumor) cells causing apoptotic cell death. We have selected the HSV-tk as a therapeutic gene in this study because the HSV-tk/GCV system was shown to have a pronounced ''bystander effect'' that led to the destruction of untransduced neighboring tumor cells thus enhancing the anticancer effect. 15 We hypothesized that the novel Ad vector based on the genome of avian Ad CELO expressing the HSV-tk gene would combine useful properties of CELO vector backbone with a pronounced anticancer activity of the HSV-tk/GCV system. In this study, we replaced the ''nonessential'' region in the CELO genome with an expression cassette encoding the HSV-tk under the control of human cytomegalovirus (HCMV) promoter. We sought to investigate the anticancer efficacy of Ad vector CELO-TK in cultured cancer cells and in subcutaneous murine melanoma tumor transplants in immunocompetent mice.
Methods

Cell lines
The 293 (human embryonic kidney) cell line was kindly provided by FL Graham (McMaster University, Hamilton, Ontario, Canada). A549 (human lung adenocarcinoma), H1299 (human lung adenocarcinoma), and Hep3B (human hepatocellular carcinoma) were obtained from the American Type Culture Collection (ATCC, Manassas, VA). Leghorn male hepatoma (LMH) cells were generously provided by M Cotten (Institute for Molecular Pathology, Vienna, Austria). The B16F1 (murine melanoma) cell line was kindly provided by G Deichman (Blokhin Cancer Research Center, Moscow, Russia). All cell lines were maintained in DMEM (Sigma-Aldrich, St Louis, MO) supplemented with 10% fetal bovine serum (FBS) (HyClone Laboratories, Logan, UT).
Plasmid vectors
Shuttle plasmids for construction of CELO and Ad5 vectors were made as follows. An NdeI-SalI fragment from pGT60hTRAIL (Invivogen, San Diego, CA) containing the HSV-tk gene was subcloned between the SmaI and EcoRV sites of pBluescript II SK( þ ) polylinker (Invitrogen, Carlsbad, CA) resulting in the plasmid named pBssk/TK. A BamHI-PstI fragment of pBssk/ TK containing the HSV-tk gene without additional ATG codons was subcloned between the EcoRV and PstI sites of pBluescript II SK( þ ). The NotI-HincII fragment from the resulting plasmid pBs/TK was subcloned between the ApaI and NotI sites of pRc/HCMV (Invitrogen) resulting in the expression plasmid vector named pRc/TK, which carries the HSV-tk gene under the control of the HCMV promoter. The shuttle plasmid vector pCBEDRV/TK was constructed by subcloning the PvuII-BglII fragment containing the HSV-tk expression cassette from pRc/TK into the EcoRV site of the right-hand CELO genome fragment contained in pCBEDRV. pCBEDRV is a derivate of pCBE, kindly provided by V Krougliak (Mount Sinai School of Medicine, New York, NY). pCBEDRV carries CELO sequences corresponding to 88.8-100 map units (m.u.) of the wt (strain Phelps) CELO genome with the deletion of a 1954 bp EcoRV fragment (95.2-99.7 m.u.). The same PvuII-BglII fragment from pRc/TK was also subcloned between the BglII and EcoRV sites of the pDE1sp1A shuttle vector (Microbix Biosystems, Toronto, Ontario, Canada), which contains left-hand part of the Ad5 genome (0-16.1 m.u.) with an E1-region deletion (1-9.8 m.u.). The resulting shuttle plasmid was designated pRW215. To verify the functional activity of HSV-tk in the shuttle plasmid vectors, monolayers of 293 and LMH cells were transiently transfected with the corresponding plasmids and cell viability in the presence or absence of the prodrug (GCV) was determined.
The EGFP gene was obtained from the plasmid pEGFP-1 (BD Biosciences-Clontech, Palo Alto, CA). A NotI-EcoRV fragment of pEGFP-1 encompassing the EGFP gene was subcloned between the NotI and EcoRV sites of pcDNA3.1/Zeo( þ ) (Invitrogen) giving pcEGFP. The expression cassette carrying the EGFP gene under the control of the HCMV-promoter was excised from pcEGFP with BglII and PvuII and then subcloned into the EcoRV site of pCBEDRV and also between the BglII and EcoRV sites of pDE1sp1A resulting, respectively, in the CELO and Ad5 shuttle plasmids pRW325 and pRW11. Expression of EGFP from these two shuttle plasmids was verified by transient transfection of 293 cell monolayers followed by fluorescence microscopy.
Adenovirus vectors
Avian Ad CELO (wt, strain Phelps) was used as a backbone for CELO vectors. The recombinant Ad vectors CELO-TK and CELO-EGFP were made by homologous recombination in LMH cells upon cotransfection of wt CELO genomic DNA digested with SwaI and the shuttle plasmid vectors pCBEDRV/TK or pRW325. These CELO vectors have the expression cassette inserted into an EcoRV deletion that encompasses nt. 41,731-43,684 of the wt CELO genome. CELO-GFP is similar to CELO-EGFP but it carries the wt, nonenhanced version of the GFP gene. The construction of CELO-GFP was described previously. 16 The first-generation Ad5-based vectors Ad5-EGFP and Ad5-TK were constructed by cotransfection of 293 cells with pRW11 or pRW215 shuttle plasmids, respectively, and pJM17 (Microbix Biosystems). These Ad5-based vectors have the E1 region deleted and carry the expression cassette at the site of the deletion. Vectors were plaque-purified three times on monolayers of LMH cells (CELO vectors) or 293 cells (Ad5 vectors).
Large-scale preparations of CELO vectors were made using a modification of the technique described by Laver et al. 8 Seeding stocks of CELO vectors were obtained by infection of LMH cell monolayers with recombinant CELO vectors at a multiplicity of infection (MOI) of 10 PFU/cell. At day 3 postinfection, cells were collected and subjected to three freeze-thaw cycles to release virions. Eleven-day-old specific pathogen free (SPF) chicken embryos (Blokhin Cancer Research Center) were infected by inoculation into the allantoic sac with 10 7 PFU/embryo of a seeding stock that had been diluted to 200 ml with serum-free DMEM. Eggs were incubated at 371C and at day 3 postinfection, embryos were transferred to 41C to prevent contamination of samples with blood during the collection of the allantoic fluid. After 12 hours, allantoic fluid (ca. 10 ml/embryo) was collected and pooled. The allantoic fluid was clarified by centrifugation at 3 K RPM for 15 minutes at 41C to remove high molecular weight aggregates. Supernatants were collected, transferred to SW-28 centrifuge tubes (30 ml/tube) (Beckman Coulter, Fullerton, CA), underlaid with 5 ml of CsCl cushion (60.9 g CsCl/100 ml, Z ¼ 1.375), and centrifuged for 2 hours at 25 K RPM at 41C. Virus bands near the surface of the CsCl cushion were collected, diluted in CsCl solution (41 g CsCl/100 ml, Z ¼ 1.365), and purified by equilibrium density gradient centrifugation in a VTi-50 rotor for 18 hours at 40 K RPM at 151C. Viral bands were collected and stored at 41C. We routinely obtained an average yield of 0.4570.28 mg of viral protein (1.82 Â 10 12 71.13 Â 10 12 particles) of CELO vector per infected embryo. Ad5-based vectors were propagated in 293 cells and purified by CsCl banding as described previously. 17 Genomic DNA was extracted from samples of CsClbanded Ad vectors and analyzed by restriction digestion and PCR to verify the recombinant structure of the genomes and to ensure the absence of wt sequences in the preparations. CELO vectors were titered by plaque assay in LMH cells. Ad5 vectors were titered by plaque assay in 293 cells. The concentration of viral particles was determined by OD 260 measurements.
18 Viral preparations with a particle/PFU ratio of 100710 were used in cell culture and animal experiments.
Transduction of tumor cells in vitro and cell viability assay
For the assay of direct cytotoxicity, semiconfluent monolayers of A549 cells were grown in 24-well plates (Dow Corning, Midland, MI). Cells from three wells were trypsinized, collected, and counted (4.1 Â 10 4 cells per well). Cell monolayers in the remaining wells were infected with virus vector in 0.25 ml of serum-free DMEM (Sigma-Aldrich) at an MOI of 100 PFU/cell. DMEM supplemented with 10% FBS was added to the cells after 3 hours of adsorption at 371C. For the ''bystander effect'' assay, semiconfluent monolayers of tumor cells were grown in 60 mm plates (Dow Corning). Cells from three plates were trypsinized, collected, and counted (5.9 Â 10 5 cells per plate for A549, 9 Â 10 5 cells per plate for H1299, 5.8 Â 10 5 cells per plate for Hep3B, and 4.9 Â 10 5 cells per plate for B16). Cells in untrypsinyzed monolayers were infected with virus vectors in 1 ml of serum-free DMEM (Sigma-Aldrich) at the indicated MOI (0, 10, 100, or 1000 PFU/cell). At 3 hours postinfection at 371C, cells were washed three times with PBS (Sigma-Aldrich), trypsinized, collected, counted, mixed with uninfected cells at a ratio of 1:1, and seeded into 24-well plates at a density of 4 Â 10 4 cells per well. GCV (F Hoffmann-La Roche, Basel, Switzerland) was added to cell cultures to a final concentration of 50 mg/ml at 24 hours postinfection. At days 6-7 postinfection, cell viability was quantified in triplicate using an MTT assay (Promega, Madison, WI). Viability of mock-infected cells at the end of an experiment was considered 100%.
Animal experiments
Six-week-old female C57BL/6 mice (Blokhin Cancer Research Center) were quarantined for 1 week before tumor implantation. Tumors were established by subcutaneous injection of 1 Â 10 6 B16F1 cells in 100 ml of serum-free DMEM into the right hind flank of mice. When tumors reached a volume of ca. 100 mm 3 (10 days after tumor cell injection), mice were randomized and divided into six groups, each consisting of nine mice. Tumors were injected with PBS, CELO-GFP, or CELO-TK (1 Â 10 9 PFU per injection in 100 ml of PBS). CsCl preparations of the vectors were dialyzed against PBS prior to injections. Three needle tracks per injection were made to maximize the spread of the vectors within the tumors. The injections were repeated every 3rd day until the end of the experiment, for a total of nine injections. GCV was administered to mice by intraperitoneal injection (50 mg/kg of weight/day) starting from day 3 after the beginning of treatment and repeated daily untill the end of the experiment. Tumor dimensions were measured every 3rd day with calipers and tumor volumes were calculated as 0.5 Â length Â width 2 . Animals were euthanized when the tumor volume reached 2500 mm 3 . The experiment was repeated three times with similar results. In a separate set of mice, tumors of 500 mm 3 volume were injected intratumorally with a single dose of CELO-EGFP (10 9 PFU in 100 ml of PBS). At day 5 after injection, tumor sections were prepared and analyzed for expression of EGFP by fluorescence microscopy.
Statistical analysis
Statistical software SPSS (SPSS, Chicago, IL) was used to perform analyses. Data are presented as mean7SD. For in vitro cell viability assays and for comparison of tumor volumes in vivo, statistical analyses were carried out using one-way ANOVA or factorial ANOVA followed by Tukey's HSD test for comparisons between groups. Kaplan-Meier survival curves were plotted for the in vivo tumor experiment. The log rank test was used to compare different treatment groups. Po.05 was considered significant.
Results
CELO and Ad5 vectors
CELO-TK and CELO-EGFP are based on the CELO (FAV-1) genome with deletion of the ''nonessential'' region and the insertion of an expression cassette (encoding either HSV-tk or EGFP, under the control of HCMV promoter) in the right-to-left orientation relative to the conventional orientation of the Ad genome (Fig  1a) . These vectors are analogous to Ad5 vectors in which the ''nonessential'' E3 region has been deleted that is, they are nondefective for replication in permissive hosts (e.g. LMH cells and chicken embryos) and do not require a complementing cell line for production. 7 This feature is advantageous because the preparation of these CELO vectors in noncomplementing cell lines eliminates the problem of contamination with wt virus arising as a result of recombination with viral sequences in the genome of a complementing cell line. 19 The ''nonessential'' E3 region of Ad5 genome encodes proteins with immunomodulatory functions. 20 The ''nonessential'' region of CELO contains open reading frames (ORFs) encoding putative transmembrane glycoproteins with an immunoglobulinlike domain and potential immunomodulatory functions. 21 CELO vectors in which the ''nonessential'' region is deleted are replication-competent in avian cells. In mammalian cells, these vectors (as well as wt CELO) are replication-deficient, 7 likely as a result of the requirement for host-specific factors for the complete cycle of Ad infection. 22 Other distinguishing features of CELO vectors are: (i) the size of genome (43,804 bp for wt CELO versus 35938 bp for wt Ad5), 23 (ii) the absence of amino-acid sequence homology between predicted early proteins of CELO (except E2 region) and early proteins of human Ads, 21, 23, 24 (iii) the absence of capsid components pV and pIX, found in Ad5, 7, 24 and (iv) the presence of two fibers of different length per each penton base 25 (the long fiber of CELO interacts with coxsackievirus and Ad receptor (CAR); the receptor for the short fiber is yet unknown). Ad5-TK and Ad5-EGFP are first-generation Ad5 vectors with the E1 region deleted and an expression cassette inserted at the site of the deletion (Fig 1b) . The E3 region in these vectors is derived from dl309, an E3B region deletion-substitution mutant. 27 The deletion of the E1 region renders these vectors replication-incompetent, unless the missing functions are supplemented in trans by a complementing cell line or a helper virus.
In vitro functional activity of CELO-TK
Direct cytotoxic effect of HSV-tk is observed in the presence of nucleoside analogs and is mediated by apoptosis resulting from the arrest of cellular DNA synthesis. The selective killing of HSV-tk-expressing cells relies on the fact that HSV-encoded thymidine kinase utilizes a broad spectrum of nucleoside analogs as substrates, for example, GCV, whereas cellular thymidine kinase does not efficiently utilize GCV as a substrate. Consequently, HSV-tk-negative cells do not undergo apoptosis in response to GCV treatment. 28 To detect functional activity of the HSV-tk/GCV system in cells transduced by CELO-TK, A549 cells were infected at an MOI of 100 PFU/cell with the vector and the viability of cells in the presence or absence of GCV was determined at day 7 postinfection (Fig 2) . The addition of GCV to mock-infected cells did not produce significant cytotoxicity. CELO-TK caused significant cell death (27% compared to mock control) in the absence of GCV, and the cytotoxic effect was substantially enhanced in the presence of GCV (85%) indicating that HSV-tk was functional when delivered by transduction with CELO-TK.
Comparison of CELO-TK and Ad5-TK
We sought to compare the ability of CELO-TK and Ad5-TK to kill human cancer cells in vitro. To distinguish between cytotoxicity mediated by the expression of HSVtk and that mediated by the vector backbone and/or capsid, and to study the effect of HSV-tk on untransduced cells, we implemented a ''bystander effect'' assay. In this assay two populations of cells are cocultured, untransduced ''targets'', and transduced ''effectors'', with intercellular junctions being formed between these two populations of cells after ca. 4 hours of coculturing. 29 The ''effector'' cells were made by infection with virus vectors at increasing MOI, then these cells were cocultured with untransduced ''target'' cells at a ratio of 1:1. 29 The ''bystander effect'' is defined as ability to mediate killing of cells that are not transduced with the therapeutic gene. The product of HSV-tk activity, GCV-MP can reach neighboring cells via gap junctions and initiate apoptosis in HSV-tk-negative cells that are in contact with HSV-tkpositive cells. 28, 29 This assay reflects the situation in a tumor, where only a fraction of the cells is transduced after vector administration. H1299 cells were transduced at increasing MOI (0, 10, 100, or 1000 PFU/cell) with CELO-TK or Ad5-TK and also with CELO-EGFP or Ad5-EGFP as controls. Infected cells were cocultured with untransduced cells in the presence or absence of GCV, and cell viability was quantified at day 6 postinfection (Fig 3) . Neither of the control vectors showed cytotoxicity as compared to mock-infected cells. Ad5-TK and CELO-TK in the presence of GCV showed an MOI-dependent increase in cytotoxicity. A synergistic effect of factors of the presence of prodrug, the presence of HSV-tk gene, and the MOI with viral vectors was found (factorial ANOVA, Po.001; interaction of factors GCVnVECTORnMOI, P ¼ .012). At equal MOI, Ad5-TK was more effective than CELO-TK in killing H1299 cells (one-way ANOVA, Po.001; post hoc Tukey's HSD test;
. CELO-TK reached a level of cytotoxicity comparable to that of Ad5-TK at a 10-fold lower MOI
, that is, CELO-TK was not different from Ad5-TK when the MOI with the CELO-based vector was an order of magnitude higher than with the Ad5-based vector.
CELO-TK demonstrates anticancer effect in various tumor cell lines of mammalian origin
The ''bystander effect'' assay was used to determine whether the CELO-TK vector is efficient in tumor cell Figure 2 Cytotoxicity of CELO-TK in the presence or absence of prodrug (GCV) in the A549 human lung adenocarcinoma cell line. Cells were transduced with CELO-TK at an MOI of 100 PFU/cell. At day 7 postinfection, cell viability was quantified using an MTT assay. Open bars, absence of GCV in the medium. Gray bars, GCV was present in the medium (50 mg/ml). Statistically significant differences are indicated (one-way ANOVA, Po.001; post hoc Tukey's HSD test). Synergy between CELO-TK and GCV was found (factorial ANOVA, Po.001; interaction of factors VECTORnGCV, P ¼ .001).
lines of various origin (Fig 4) . Human (A549, Hep3B) and murine (B16) cancer cell lines were transduced at an MOI of 1000 PFU/cell with CELO-TK or CELO-GFP as a control, then, after 3 hours of infection, mixed with untransduced cells at a ratio of 1:1, seeded to plates in serum-containing medium in the presence or absence of GCV and the viability of cells was determined at day 7 postinfection. CELO-TK in the presence of GCV caused killing of 92% of A549, 94% of Hep3B, and 64% of B16 cells as compared to the mock-infected control (Fig 4) . Significant cytotoxicity was not observed in the control groups. We conclude that CELO-TK-mediated delivery of the HSV-tk gene resulted in expression and functional activity of HSV-tk protein in human and murine tumor cells.
Anticancer activity of CELO-TK in B16 subcutaneous melanoma tumors
We used subcutaneous transplants of murine B16 melanoma cells in syngeneic, immunocompetent C57BL/ 6 mice as a tumor model for the evaluation of the efficacy of CELO-TK in vivo. Although both syngeneic and xenograft rodent tumor models have limitations in their ability to predict anticancer drug activity in humans, 30, 31 syngeneic murine tumors in immunocompetent mice is often the animal model of choice for preclinical evaluation of HSV-tk-expressing vectors. 32 Whereas the ''bystander effect'' of HSV-tk in vitro and in immunodeficient animals depends on the spread of GCV-MP through gap junctions and with apoptotic vesicles, the use of immunocompetent animal tumor models allows for the activation of the immune system, which results in addition of another modality to the in vivo ''bystander effect'' of HSV-tk. 33, 34 To determine the feasibility of treating subcutaneous B16 tumors with CELO vectors we first performed intratumoral injection of CELO-EGFP, which carries the reporter gene EGFP, to visualize in vivo transduction. Recombinant CELO-EGFP effectively transduced B16 tumors along the needle track of injection (Fig 5a) .
To assess the efficacy of CELO-TK in vivo, established subcutaneous B16 tumors (mean volume of 100 mm 3 ) were injected intratumorally with CELO-TK or controls (buffer or CELO-GFP). Multiple administrations of each vector were performed to achieve even distribution of the vectors within tumors and to increase the dose. GCV administration was started 3 days after the first injection of vectors. B16 cells form aggressively growing tumors in C57BL/6 mice (Fig 5b) . At day 9 after the start of treatment, that is, after three rounds of vector injection, the mean size of the tumors in control groups reached a volume of 1400-1800 mm 3 representing 14-to 18-fold growth. The tumor growth in animals treated with CELO-TK and GCV was suppressed compared to control groups (mean volume 500 mm 3 or five-fold growth). Statistically significant interaction of GCV and HSV-tk was found indicating that the HSV-tk delivered by CELO-TK was functional in vivo.
In the group treated with buffer, all animals had to be euthanized by day 15 after the start of treatment because each tumor size exceeded 2500 mm 3 (median survival of 12 days) (Fig 5c) . Treatment with either vector in the absence of GCV and treatment with the buffer or the control CELO-GFP vector in the presence of GCV did not significantly influence median survival for these groups (12-15 days) (Fig 5c and d) . The only group to show significantly prolonged median survival was that in which tumors were injected with CELO-TK followed by GCV administration. Although complete tumor regression was not observed and eventually all animals in the CELO-TK þ GCV treatment group were euthanized because of continuous tumor growth, the median survival in this group was extended to 23 days, that is, twice of that of buffer-treated control (Fig 5d) .
Discussion
We constructed a recombinant avian Ad vector encoding the HSV-tk gene driven by the HCMV promoter in place of the ''nonessential'' region of the CELO genome to test the hypothesis that the CELO-TK vector, which features an efficient production system, could be an effective anticancer vector. With our vectors CELO-TK and CELO-EGFP we observed robust yields in chicken embryos with an average of 1.8 Â 10 12 particles of CELO vectors obtained per infected egg. Although there is the evidence that CELO vectors of various configurations can be constructed, it is not known if alterations in CELO sequences outside of the ''nonessential'' region would result in a vector that could be produced with comparable effectiveness. 7, 35, 36 In our experiments, the CELO-TK vector had good in vitro and in vivo anticancer activity. It is known that CELO vectors can mediate the transduction of mammalian tumor cells and mediate expression of reporter genes in vitro. 7, 26 Direct extrapolation of the data with reporter genes cannot give accurate predictions of anticancer activity since reporter genes only indicate the efficacy of transduction/expression and do not measure the efficacy of cell death. In addition, the HSV-tk gene has a ''bystander effect'' causing the death of untransduced cells, thereby enhancing the effect of initial transduction. The extent of the ''bystander effect'' is determined largely by the expression of connexins in tumor cells because the spread of GCV-MP occurs through gap junctions. 37 Therefore, the presence of the ''bystander effect'' in vitro cannot be assumed based on the data with reporter genes. Recently, a CELO vector expressing p53 tumor suppressor was reported. 9 It was concluded that CELO is able to mediate the delivery of p53 to tumor cells as judged from expression of reporter genes under the control of a p53-responsive promoter. Here we show for the first time that a CELO vector can be used to deliver a functional therapeutic gene to a panel of mammalian tumor cells and mediate anticancer activity in cell culture, including the death of untransduced cells due to the ''bystander effect''.
We report that significant cytotoxicity was mediated by CELO-TK in the absence of GCV (Fig 2) . Other CELO vectors based on the same platform also displayed cytotoxicity in tumor cell lines independent of the inserted transgene or the presence of the HCMV promoter in the vector backbone when the MOI was higher than 10 (data not shown). This backbone-mediated cytotoxicity could also be the mechanism of anticancer activity of a GFPexpressing CELO vector in human tumor xenografts in nude mice. 9 One possible explanation for this cytotoxicity is the synthesis of proteins from the vector backbone with functions that are similar to those of human Ad E1A. 38 Alternatively, this phenomenon might be a result of abortive virus replication in a xenogeneic host as has been described for ovine Ad, another vector with genome that does not have conventional E1, E3, and E4 regions. 39 Whereas this nonspecific cytotoxicity is not of major concern for cancer gene therapy vectors applied by intratumoral administration, it might be of importance if intravenous administration of this type of vector is contemplated.
Our in vitro experiments in human H1299 tumor cells have shown that CELO-TK is less cytotoxic in the presence of GCV at an equal MOI as compared to Ad5-TK. Other CELO vectors were also shown to transduce and/or express less efficiently in mammalian cells than their Ad5-based counterparts, at least in the case of HCMV-driven expression cassettes. 26 This phenomenon may result from reduced activity from the HCMV promoter within the context of the CELO vector (in Ad5 vectors E4 proteins are known to transactivate the HCMV promoter), 40, 41 from lower affinity of CELO fiber for mammalian CAR, from less efficient intracellular trafficking of avian Ad to the nucleus of mammalian cells, or a combination of these factors. Further research is necessary to evaluate if the use of other promoters that are less dependent on NF-kB activation than the HCMV promoter (e.g. avian retrovirus promoter RSV) or capsid modifications 42 have the potential to improve the level of CELO vectors transduction/expression in mammalian cells.
We observed significant suppression of B16 melanoma tumors in vivo after treatment with CELO-TK/GCV. For established B16 melanoma tumors, complete tumor ablation is not achievable even when the tumor cells are stably transduced with HSV-tk (i.e. 100% of cells carry the gene). 43, 44 With CELO-TK/GCV, we observed a twofold extension of survival time, which indicates that CELO-TK/GCV was ''highly'' active according to the NCI classification of anticancer drug activities in murine B16 allografts. 30 Clinically, there are no effective monotherapies for melanoma, consequently chemotherapy drugs and biologics are used in combination. 45 The ''bystander effect'' of HSV-tk can be improved by concomitant treatment with hydroxyurea, 46 suggesting a possible combination of modalities for clinical treatment of melanoma.
Ad5 vectors can be engineered to replicate in tumors and can also be ''armed'' with therapeutic transgenes (e.g. HSV-tk). [47] [48] [49] [50] This strategy cannot be used with CELO vectors, which are naturally defective for replication in mammalian cells. However, it was suggested that with replication-competent vectors the expression of cytotoxic transgenes (e.g. HSV-tk) might counteract the oncolytic effect, 51, 52 which itself could also be limited in certain solid tumors. 53 This complex interaction of transgene function and vector replication is not relevant for replication-deficient vectors (e.g. first-generation Ad5 vectors or CELO). At the same time, the even distribution of both replication-deficient and replication-competent vectors could be theoretically achieved by ''diffuse injection''. 54 Therefore, it remains to be determined under various experimental conditions whether HSV-tk-expressing replication-competent and replication-deficient vectors can produce comparable therapeutic effect in vivo.
Ad CELO provides many advantages as anticancer vector including the cost-effectiveness of producing large quantities of vectors, the absence of pre-existing immunity to CELO in the human population, the absence of crossreactivity of anti-Ad5 antibodies to CELO, natural deficiency for replication in mammalian cells, and the ability to grow in noncomplementing avian cells. 8, 9 In addition, the feasibility of deleting the long fiber from the CELO genome was demonstrated, providing an opportunity for implementation of ''retargeting'' strategies to CELO vectors. 26 Although wt CELO virus was shown to induce tumors in newborn hamsters, 55 this does not directly indicate that wt CELO is carcinogenic for humans since it was not shown to cause cancer in immunocompetent animal models. With respect to the safety of CELO-TK, this vector expresses the prodrug-activating enzyme HSV-tk, a safety strategy often employed in gene therapy vectors. 28 Finally, the risk-benefit ratio determines whether an anticancer treatment is accepted or remains merely experimental.
